352 related articles for article (PubMed ID: 33462444)
1. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.
Hickey TE; Selth LA; Chia KM; Laven-Law G; Milioli HH; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell SN; Stelloo S; Iggo R; Alexandrou S; Caldon CE; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Lim E; Carroll JS; Tilley WD
Nat Med; 2021 Feb; 27(2):310-320. PubMed ID: 33462444
[TBL] [Abstract][Full Text] [Related]
2. Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action.
Yu Z; He S; Wang D; Patel HK; Miller CP; Brown JL; Hattersley G; Saeh JC
Clin Cancer Res; 2017 Dec; 23(24):7608-7620. PubMed ID: 28974548
[No Abstract] [Full Text] [Related]
3. Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor-Positive Breast Cancer.
Wei L; Gao H; Yu J; Zhang H; Nguyen TTL; Gu Y; Passow MR; Carter JM; Qin B; Boughey JC; Goetz MP; Weinshilboum RM; Ingle JN; Wang L
Cancer Res; 2023 Feb; 83(3):456-470. PubMed ID: 36469363
[TBL] [Abstract][Full Text] [Related]
4. AIB1 sequestration by androgen receptor inhibits estrogen-dependent cyclin D1 expression in breast cancer cells.
De Amicis F; Chiodo C; Morelli C; Casaburi I; Marsico S; Bruno R; Sisci D; Andò S; Lanzino M
BMC Cancer; 2019 Nov; 19(1):1038. PubMed ID: 31684907
[TBL] [Abstract][Full Text] [Related]
5. Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib.
Ji W; Shi Y; Wang X; He W; Tang L; Tian S; Jiang H; Shu Y; Guan X
Int J Biol Sci; 2019; 15(3):522-532. PubMed ID: 30745839
[TBL] [Abstract][Full Text] [Related]
6. Treating ER+ Breast Cancer with CDK4/6 Inhibitors.
Cancer Discov; 2017 Aug; 7(8):OF4. PubMed ID: 28626036
[TBL] [Abstract][Full Text] [Related]
7. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.
Cochrane DR; Bernales S; Jacobsen BM; Cittelly DM; Howe EN; D'Amato NC; Spoelstra NS; Edgerton SM; Jean A; Guerrero J; Gómez F; Medicherla S; Alfaro IE; McCullagh E; Jedlicka P; Torkko KC; Thor AD; Elias AD; Protter AA; Richer JK
Breast Cancer Res; 2014 Jan; 16(1):R7. PubMed ID: 24451109
[TBL] [Abstract][Full Text] [Related]
8. Androgen Triggers the Pro-Migratory CXCL12/CXCR4 Axis in AR-Positive Breast Cancer Cell Lines: Underlying Mechanism and Possible Implications for the Use of Aromatase Inhibitors in Breast Cancer.
Azariadis K; Kiagiadaki F; Pelekanou V; Bempi V; Alexakis K; Kampa M; Tsapis A; Castanas E; Notas G
Cell Physiol Biochem; 2017; 44(1):66-84. PubMed ID: 29131020
[TBL] [Abstract][Full Text] [Related]
9. The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation.
Garay JP; Karakas B; Abukhdeir AM; Cosgrove DP; Gustin JP; Higgins MJ; Konishi H; Konishi Y; Lauring J; Mohseni M; Wang GM; Jelovac D; Weeraratna A; Sherman Baust CA; Morin PJ; Toubaji A; Meeker A; De Marzo AM; Lewis G; Subhawong A; Argani P; Park BH
Breast Cancer Res; 2012 Feb; 14(1):R27. PubMed ID: 22321971
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines.
Rizza P; Barone I; Zito D; Giordano F; Lanzino M; De Amicis F; Mauro L; Sisci D; Catalano S; Dahlman Wright K; Gustafsson JA; Andò S
Breast Cancer Res; 2014 Feb; 16(1):R21. PubMed ID: 24552459
[TBL] [Abstract][Full Text] [Related]
12. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
13. Androgen Receptor-Mediated Growth Suppression of HPr-1AR and PC3-Lenti-AR Prostate Epithelial Cells.
Kim YC; Chen C; Bolton EC
PLoS One; 2015; 10(9):e0138286. PubMed ID: 26372468
[TBL] [Abstract][Full Text] [Related]
14. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
[TBL] [Abstract][Full Text] [Related]
15. Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and -negative breast cancer cells.
Lin HY; Sun M; Lin C; Tang HY; London D; Shih A; Davis FB; Davis PJ
J Steroid Biochem Mol Biol; 2009 Feb; 113(3-5):182-8. PubMed ID: 19159686
[TBL] [Abstract][Full Text] [Related]
16. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
[TBL] [Abstract][Full Text] [Related]
17. Revisiting Androgen Receptor Signaling in Breast Cancer.
Dai C; Ellisen LW
Oncologist; 2023 May; 28(5):383-391. PubMed ID: 36972361
[TBL] [Abstract][Full Text] [Related]
18. Targeting androgen receptor in estrogen receptor-negative breast cancer.
Ni M; Chen Y; Lim E; Wimberly H; Bailey ST; Imai Y; Rimm DL; Liu XS; Brown M
Cancer Cell; 2011 Jul; 20(1):119-31. PubMed ID: 21741601
[TBL] [Abstract][Full Text] [Related]
19. The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
Amaral C; Augusto TV; Almada M; Cunha SC; Correia-da-Silva G; Teixeira N
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165661. PubMed ID: 31891807
[TBL] [Abstract][Full Text] [Related]
20. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
